In addition, Sage announced that its Board has unanimously rejected the unsolicited, nonbinding proposal it received from Biogen Inc. (Nasdaq: BIIB) (“Biogen” on January 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
on January 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share
(20min delay)